Moods Disorders Completed Phase 4 Trials for Aripiprazole (DB01238)

Also known as: Mood Disorders / Mood Disorder

IndicationStatusPhase
DBCOND0058256 (Moods Disorders)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00312598Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine